Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The biggest approval headlines of the past week came from well-established molecules, as the US FDA cleared a major new indication outside of diabetes for AstraZeneca PLC’s Farxiga and a higher-dose nasal spray formulation of the opioid antagonist naloxone, Hikma Labs Inc.’s Kloxxado.

The agency had closed out the previous week with a novel oncology agent from ADC Therapeutics SA, Zynlonta, bringing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers